Second (Multiple agents with various brand names)

Description

Second-line colorectal cancer treatment typically involves combination chemotherapy regimens such as FOLFIRI (leucovorin, fluorouracil, irinotecan) or FOLFOX (leucovorin, fluorouracil, oxaliplatin), often combined with targeted agents like bevacizumab, cetuximab, or panitumumab. These regimens are standard palliative treatments for patients with metastatic colorectal cancer who have progressed on initial therapy. The specific combination chosen depends on prior treatments received, molecular tumor characteristics, and patient performance status.

Mechanism of Action

Second-line regimens combine cytotoxic agents that interfere with DNA synthesis and cell division through multiple pathways. Fluorouracil inhibits thymidylate synthase, irinotecan targets topoisomerase I, and oxaliplatin forms DNA crosslinks, while targeted agents may inhibit VEGF signaling or EGFR pathways depending on the specific combination used.

Molecular Targets

Side Effects

Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.

Clinical Trials